Cogent Biosciences announced plans to launch bezuclastinib for Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) in the second half of 2026, supported by positive Phase 3 trial data. The company ended Q1 2026 with $866.4 million in cash, enough to fund operations through 2028. Research and development expenses rose due to pipeline advancements, while net loss increased to $97.4 million. Upcoming milestones include NDA submissions, clinical trial presentations, and new drug development programs.
Barclays increased its price target for Carvana to $94 and maintained an "Overweight" rating, reflecting confidence in the company's strong operational growth, including a 40% rise in retail unit sales and a record Adjusted EBITDA of $672 million. Ho...
An Exxon Mobil executive sold shares valued between $15,000 and $50,000 after the company's stock surged over 150% in five years, trading near its 52-week high. The strong performance is driven by favorable market conditions, including geopolitical t...
East West Bancorp is set to report strong Q2 2026 earnings with an expected EPS of $2.61 and revenue of $785.94 million, reflecting an 11.8% revenue increase and 14.5% EPS growth year-over-year. The bank shows robust financial health with expanding d...
AerCap has selected GE Aerospace's GEnx-1B engines to power 15 additional Boeing 787 Dreamliners, reinforcing its position as the largest owner of these aircraft. The GEnx engine is known for its high reliability and long service life, with a 99.98% ...
Crédit Agricole Brie Picardie conducted share buybacks totaling 13,057 shares from July 13 to July 17, 2026, with daily volumes ranging from 1,605 to 5,095 shares. These transactions were carried out under Article 5 of the Market Abuse Regulation (MA...
